کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
8941082 1644897 2018 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Macitentan in daily clinical practice: A single centre, 1-year experience
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی پزشکی ریوی و تنفسی
پیش نمایش صفحه اول مقاله
Macitentan in daily clinical practice: A single centre, 1-year experience
چکیده انگلیسی
The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events. Our aim was to describe a single centre's experience of the utilization of macitentan in patients with PAH in clinical practice settings. Thirteen patients with different aetiologies and previous PAH treatments were studied. After 12 months of macitentan treatment, 11 patients improved their functional class (FC), all patients improved their 6-minute walk distance (6MWD) test, and 10 patients lowered their NT-proBNP plasma levels. Additionally, cardiac imaging parameters were also improved. No cases resulted in hospitalization, septostomy, transplant or death.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Pulmonology - Volume 24, Issue 3, May–June 2018, Pages 170-173
نویسندگان
, , , , , ,